Reductions in cardiovascular risk after bariatric surgery
In November 2023, the FDA granted approval for Zepbound (tirzepatide) for chronic weight management in adults with obesity (body mass index 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbid condition such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease
Common side effects of semaglutide include nausea, constipation, diarrhea, and decreased appetite
This process is especially important for detoxifying alcohol and other harmful substances
While not yet FDA-approved, it has shown impressive results in clinical trials, with average weight loss exceeding 24% of body weight
Your starting weight, diet quality, protein and fiber intake, sleep, stress, and activity level all influence outcomes